Metformin — cheap, safe, and available everywhere — is being tested in IMPEDE-PKD, the largest clinical trial ever conducted in PKD with 1,174 patients. If it works, it could immediately transform PKD treatment worldwide.
Background
Metformin has been used safely for decades in diabetes. Researchers discovered it activates AMPK, which inhibits two key drivers of cyst growth: mTOR signaling and CFTR-mediated fluid secretion. The prior Phase 2 study (TAME-PKD) showed metformin was safe in PKD patients and showed an encouraging (but not statistically significant) trend toward slowing kidney growth. Now, IMPEDE-PKD is the definitive test — with 1,174 patients, it's powered to detect even modest benefit.
How It Works
Metformin activates AMPK through inhibition of mitochondrial complex I, leading to increased AMP:ATP ratio. In PKD-relevant pathways: (1) AMPK inhibits mTORC1 via TSC2 phosphorylation, reducing cyst cell proliferation; (2) AMPK phosphorylates and inhibits CFTR chloride channels, reducing fluid secretion into cysts; (3) AMPK inhibits ACC and lipogenesis required for rapidly dividing cyst cells. The maximum dose tested is 2000mg daily — the same dose used in diabetes.
Clinical Trial Details
IMPEDE-PKD (NCT04939935) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial led by the University of Queensland. 1,174 ADPKD patients receive metformin (up to 2000mg daily) or placebo with a primary endpoint of annualized change in TKV. Started November 2022 with estimated completion in 2027. This is the largest PKD-specific clinical trial ever conducted.
Why It's Promising
If IMPEDE-PKD shows benefit, the impact is immediate and enormous. Metformin costs pennies per day, is available worldwide including low-income countries, has decades of safety data, and could be prescribed tomorrow by any physician. It would be the most accessible PKD treatment possible — a true game-changer for the global PKD community.
Limitations & Concerns
GI side effects (nausea, diarrhea) are common and may cause unblinding. The TAME-PKD Phase 2 trend was not statistically significant. AMPK activation is a pleiotropic mechanism — many drugs have failed when promising preclinical AMPK data didn't translate to humans. Results not expected until 2027.